Mirabegron Teva

Mirabegron, the active ingredient in Mirabegron Teva, is a beta‑3 adrenergic receptor agonist presented as an oral tablet for oral use. It is indicated for the treatment of overactive bladder symptoms such as urinary urgency, frequency and urge incontinence in adults.

GNH USA supplies Mirabegron Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Our distribution network ensures timely delivery and compliance with local regulatory requirements.

Mirabegron is used to manage conditions related to overactive bladder and urinary urgency. - Overactive bladder: reduces urinary urgency, frequency and urge incontinence. - Urinary urgency: lessens the sudden need to void. - Urinary frequency: decreases the number of daytime voids. - Urge urinary incontinence: helps control accidental leakage.

Adverse reactions reported with Mirabegron vary in frequency and severity.

Common Side Effects: - Dry mouth: sensation of reduced salivation. - Headache: mild to moderate pain in the head. - Hypertension: increase in blood pressure. - Nasopharyngitis: inflammation of the nasal passages and throat. - Constipation: difficulty passing stools. - Dizziness: feeling light‑headed or unsteady.

Serious or Rare Side Effects: - Severe hypertension: markedly elevated blood pressure requiring medical attention. - Urinary retention: difficulty emptying the bladder. - Tachycardia: abnormally fast heart rate. - Angioedema: swelling of the face, lips or airway. - Hepatotoxicity: liver enzyme elevations or injury.

Before prescribing Mirabegron, clinicians should consider several precautionary measures to ensure patient safety. - Blood pressure monitoring: check baseline and periodically during therapy. - Cardiovascular assessment: evaluate history of arrhythmias or heart disease. - Renal function: adjust use in patients with severe renal impairment. - Concomitant antihypertensives: monitor for additive blood pressure effects. - Pregnancy and lactation: use only if potential benefit justifies risk. - Store below 25°C: keep in the original pack, protect from moisture.

Mirabegron can affect the plasma concentrations of several co‑administered medicines through metabolic pathways.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase Mirabegron exposure. - Antihypertensive agents (e.g., beta‑blockers, ACE inhibitors): risk of reduced blood pressure control.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates (e.g., midazolam, calcium channel blockers): possible altered levels. - Diuretics: additive effect on blood pressure. - Anticholinergic drugs: may diminish therapeutic benefit for bladder symptoms.